



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/602,663	06/25/2003	Pierre Charneau	3495.0199-01

CONFIRMATION NO. 8007

FORMALITIES LETTER



OC000000011185102

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER
 LLP
 1300 I STREET, NW
 WASHINGTON, DC 20005

Date Mailed: 11/05/2003

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents
 P.O. Box 1450

Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



PATENT
Customer No. 22,852
Attorney Docket No. 03495.0199-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Pierre CHARNEAU et al.) Group Art Unit: 1645
)
Serial No.: 10/602,663) Examiner: Unassigned
)
Filed: June 25, 2003)
)
For: USE OF TRIPLEX STRUCTURE)
DNA IN TRANSFERRING)
NUCLEOTIDE SEQUENCES)

Commissioner for Patents and Trademarks
Washington, DC 20231

Sir:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

This paper is being filed in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("the Notice"), mailed November 5, 2003.

In the Notice, the Office states that Applicants failed to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. Applicants enclose and file herewith a paper copy of Sequence Listing; a Request for Transfer of Form Under 37 C.F.R. § 1.821(e), requesting that the computer readable copy of the Sequence Listing filed in Application No. 09/688,990 be used as the computer readable copy of the Sequence Listing in the instant application; and a Statement to Support Filing and Submission in Accordance


with 37 C.F.R. §§ 1.821-1.825. Applicants respectfully submit that these filings bring the application into compliance with the requirements of 37 C.F.R. §§ 1.821-1.825.

To the extent any extension of time under 37 C.F.R. § 1.136 is required to obtain entry of this response, such extension is hereby respectfully requested and authorization is hereby granted to charge any such extension fee to our Deposit Account No. 06-0916. If there are any fees due under 37 C.F.R. §§ 1.16 or 1.17 which are not enclosed herewith, please similarly charge such fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 5, 2004

By: 
Kenneth J. Meyers
Reg. No. 25,146



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0199-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Pierre CHARNEAU et al.)	
)	
Application No.: 10/602,663)	Group Art Unit: 1645
)	
Filed: June 25, 2003)	Examiner: Unassigned
)	
For: USE OF TRIPLEX STRUCTURE DNA)	
IN TRANSFERRING NUCLEOTIDE)	
SEQUENCES)	

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION
IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. The submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;
2. The content of the attached paper copy of Sequence Listing and the computer readable form of the Sequence Listing filed in parent application No. 09/688,990, filed October 17, 2000, are identical; and
3. All statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the


like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

If any fees are necessary for the submission of the sequence listing, please charge our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 5, 2004

By: 
Kenneth G. Meyers
Reg. No. 25,146